Autologous Stem Cell & Non-stem Cell Therapies Market Size, Share, Trends, Demand, Growth and Competitive Outlook | Johnson & Johnson, Vericel Corporation, Novartis AG

Autologous stem-cell transplantation is a type of transplant where undifferentiated cells or stem cells are taken from an individual, gathered, and then reintroduced to that same individual. Because hematopoietic stem cells (the precursors of blood cells) are frequently utilized in hematopoietic stem cell transplantation, cardiac cells are sometimes utilized to mend damage resulting from heart attacks. Autologous stem cell transplantation and allogeneic stem cell transplantation are two forms of stem cell transplantation. Autologous stem-cell transplantation is also referred to as autogenic or autogenous stem-cell transplantation, often abbreviated as auto-SCT.

The increasing occurrence of cancer and diabetes across all age groups is the primary factor fueling the growth rate of the autologous stem cell and non-stem cell-based therapies market. A key factor contributing to market growth is the emergence of innovative autologous stem cell-based treatments in regenerative medicine. Additionally, the rising population of elderly individuals and the surge in demand for therapies based on autologous stem cells and non-stem cells are the key factors that will boost market growth. Additional important elements like increasing healthcare awareness and supportive reimbursement policies will support the market growth rate.

The global autologous stem cell & non-stem cell therapies market, valued at US$3.10 billion in 2023, is forecasted to grow at a robust CAGR of 32.5%, reaching US$5.6 billion in 2024 and an impressive US$22.3 billion by 2032.

Updated Version of Sample Report Included:
https://www.marketdigits.com/request/sample/4930

Major Players in Autologous Stem Cell & Non-stem Cell Therapies Markets are:
Gilead Sciences Inc. (US), Bristol-Myers Squibb Company (US), Johnson & Johnson (US), Vericel Corporation (US), Novartis AG (Switzerland), JW (Cayman), Therapeutics Co. Ltd (China), Iovance Biotherapeutics Inc. (US), APAC Biotech (India), Regrow Biosciences Pvt Ltd. (India), healiva SA (Switzerland) Tegoscience (South Korea), ImmunoACT (India), CARsgen Therapeutics Holdings Limited (China), IASO Biotherapeutics (China), Pharmicell Co. Ltd (South Korea), Anterogen Co. Ltd. (South Korea), Green Cross Holdings Co. Ltd. (GC Cell) (Republic of Korea), Sanpower Group Co. Ltd. (Dendreon Pharmaceuticals LLC) (China)

Industry News:

In April 2024, Bristol-Myers Squibb Company (US) entered into a worldwide capacity reservation and supply agreement with Cellares (US) for the manufacturing of CAR T-cell therapies using Cellares's automated & high-throughput manufacturing platform called Cell Shuttle.

In October 2023, Kite Pharma a subsidiary of Gilead Sciences, Inc. (US) collaborated with Epicrispr Biotechnologies, Inc. (US) for the uptake of regulation technology for the development of next-generation cancer cell therapies, with the enhancement of CAR T cell functionality.

"Connect with our team of research specialists and unlock the optimal solution for driving your business growth"

Global Autologous Stem Cell & Non-stem Cell Therapies Market Segmentation:

By Product:
Neurodegenerative disorders
Autoimmune diseases
Cancer and Tumours
Cardiovascular Diseases

By Type:
Blood Pressure monitoring devices
Pulmonary pressure monitoring devices
Intracranial pressure monitoring devices

By Application:
Hospitals
Ambulatory surgical centers
Others

Know more about this report:
https://www.marketdigits.com/autologous-stem-cell-and-non-stem-cell-therapies-market-1726809963

The following areas and countries are covered in the worldwide Autologous Stem Cell & Non-stem Cell Therapies Market file:

North America (US, Canada, Mexico)
Europe (Germany, France, UK, Russia, Italy)
Asia Pacific (China, Japan, South Korea, India, Southeast Asia)
South America (Brazil, Argentina, Colombia, etc.)
Middle East and Africa (Saudi Arabia, UAE), Egypt, Nigeria, and South Korea)

North America was the largest segment in 2023 in the autologous stem cell & non-stem cell therapies market, followed by Asia Pacific and Europe region. North America, comprising the US and Canada, is the largest regional segment in the autologous stem cell & non-stem cell therapies market. This regional segment is projected to grow at the highest CAGR during the forecast period. The increasing R&D investments in the field of autologous cell therapies and the growing focus on developing personalized therapeutics for various diseases are major factors supporting the large share of this market. The presence of a large number of major players in this region such as Gilead Sciences, Inc. (US), Bristol-Myers Squibb Company (US), Johnson & Johnson (US), Iovance Biotherapeutics, Inc. (US), Vericel Corporation (US) among others, is another key factor contributing to the large share of this market segment.

Detailed industry forecast-Brief Introduction to the research report:

Additional information on company participants
Customized reports and analyst assistance are available upon request.
Recent market developments and potential future growth opportunities
Personalized regional/country reports upon request
New data sources are being integrated.
Increased focus on data privacy and security
Increased collaboration and co-creation

Key Features of the Autologous Stem Cell & Non-stem Cell Therapies Market Report: -

Analyze competitive developments such as expansions, deployments, new product launches, and market acquisitions.

Examine the market opportunities for stakeholders by identifying higher growth sections.

To study and analyze the global Autologous Stem Cell & Non-stem Cell Therapies Market industry status and forecast including key regions.

An in-depth analysis of key product segments and application spectrum, providing strategic recommendations to incumbents and new entrants to give them a competitive advantage over others.

It provides a comprehensive analysis of key regions of the industry as well as a SWOT analysis and Porter's Five Forces analysis to provide a deeper understanding of the market.

It helps you make strategic business decisions and investment plans.
Finally, Autologous Stem Cell & Non-stem Cell Therapies Market is a valuable source of guidance for individuals and companies.

Discover More: Visit Our Website for Additional Reports!

https://www.globenewswire.com/news-release/2024/02/06/2824099/0/en/Mental-Health-Software-Market-projected-to-reach-USD-15-4-Billion-by-2030-growing-at-a-CAGR-of-18-8-during-the-forecast-period-of-2023-2030-pronounced-by-MarketDigits-in-its-recent.html

https://www.globenewswire.com/news-release/2024/02/06/2824166/0/en/Smart-Electric-Heater-Market-Surges-to-USD-3-9-Billion-by-2030-Reflecting-an-13-6-Growth-MarketDigits.html

https://www.globenewswire.com/news-release/2024/02/06/2824176/0/en/Advanced-Therapy-Medicinal-Products-Market-to-Accumulate-a-Valuation-of-USD-61-5-Billion-by-2030-Advancing-at-a-13-4-CAGR-MarketDigits.html

https://www.globenewswire.com/news-release/2024/02/06/2824289/0/en/Indoor-Farming-Market-is-Set-to-Reach-USD-94-1-Million-by-2030-with-CAGR-of-10-8-MarketDigits.html

https://www.globenewswire.com/news-release/2024/02/06/2824293/0/en/Cell-Expansion-Market-projected-to-reach-USD-39-7-Billion-by-2030-growing-at-a-CAGR-of-11-7-during-the-forecast-period-of-2023-2030-claims-by-MarketDigits-in-its-recent-study.html

About Us

Founded in 2015, MarketDigits Consulting & Advisory Pvt Ltd is a leading business research and consulting firm. Our mission is to empower clients by identifying emerging opportunities and driving revenue growth across industries. We specialize in providing comprehensive market insights, advanced technology solutions, and actionable strategies that support operational and strategic decision-making.

With a focus on the full value chain, our expert team delivers high-quality syndicate research reports, proprietary databases, and consulting services to help clients navigate today's competitive and dynamic business environment. At MarketDigits, we use advanced analysis to uncover profitable opportunities, enabling businesses to make smart decisions and achieve sustainable success.

Contact Us:

+1 510-730-3200 | +1 276-206-2055

sales@marketdigits.com

1248 CarMia Way Richmond

VA 23235, United States

This release was published on openPR.